Marine Biotechnology Division, Central Marine Fisheries Research Institute, Ernakulam North, P.B. No. 1603, Cochin, Kerala State, 682018, India.
School of Biotechnology, Amrita Vishwa Vidyapeetham, Vallikavu PO, Amritapuri, Kollam, Kerala State, 690525, India.
Arch Microbiol. 2022 Feb 18;204(3):183. doi: 10.1007/s00203-022-02784-2.
Appearance of drug-resistant microorganisms prompted researchers to unravel new environments for development of novel antimicrobial agents. Culture-supported analysis of heterotrophic bacteria associated with seaweeds yielded 152 strains, in that larger share of the isolates was embodied by Bacillus atrophaeus SHB2097 (54%), B. velezensis SHB2098 (24%), B. subtilis SHB2099 (12%), and B. amyloliquefaciens SHB20910 (10%). One of the most active strains characterized as B. atrophaeus SHB2097 (MW821482) with an inhibition zone more than 30 mm on spot-over-lawn experiment, was isolated from a seaweed Sargassum wightii, was selected for bioprospecting studies. Significant antibacterial potential was displayed by bacterial organic extract against vancomycin-resistant Enterococcus faecalis, Pseudomonas aeruginosa, methicillin-resistant Staphylococcus aureus, and Klebsiella pneumonia with minimum inhibitory concentration 6.25 µg/mL and comparable to the antibiotics ampicillin and chloramphenicol. The genes of type 1 pks (MZ222383, 700 bp) and hybrid nrps/pks (MZ222389, 1000-1400 bp) of B. atrophaeus MW821482 could be amplified. The bacterium displayed susceptibility to the commercially available antibiotic agents, and was negative for the pore-forming non-hemolytic hemolysin BL (hbl) and enterotoxin (nhe) genes, and therefore, was not pathogenic. The bacterium was found to possess genes (1000-1400 bp) involved in the biosynthesis of siderophore-class of compounds (MZ222387 and MZ222388) that showed 99% of similarity in BLAST search, and showed production of siderophore. Noteworthy antibacterial activities against clinically important pathogenic bacteria in conjunction with occurrence of genes coding for antimicrobial metabolites inferred that the marine heterotrophic bacterium B. atrophaeus SHB2097 could be used for the development of antibacterial agents against the emerging antibiotic resistance.
耐药微生物的出现促使研究人员探索新的环境来开发新型抗菌药物。对与海藻相关的异养细菌进行了培养支持分析,得到了 152 株菌株,其中分离株中较大比例为萎缩芽孢杆菌 SHB2097(54%)、解淀粉芽孢杆菌 SHB2098(24%)、枯草芽孢杆菌 SHB2099(12%)和地衣芽孢杆菌 SHB20910(10%)。在斑点覆盖平板实验中,具有超过 30mm 抑菌圈的最活跃菌株之一被鉴定为萎缩芽孢杆菌 SHB2097(MW821482),从海藻 Sargassum wightii 中分离出来,被选为生物勘探研究。细菌有机提取物对万古霉素耐药粪肠球菌、铜绿假单胞菌、耐甲氧西林金黄色葡萄球菌和肺炎克雷伯菌具有显著的抗菌潜力,最小抑菌浓度为 6.25µg/mL,与抗生素氨苄西林和氯霉素相当。可以扩增萎缩芽孢杆菌 MW821482 的 1 型 pks(MZ222383,700bp)和杂合 nrps/pks(MZ222389,1000-1400bp)基因。该细菌对市售抗生素药物敏感,且不携带孔形成非溶血溶血素 BL(hbl)和肠毒素(nhe)基因,因此无致病性。该细菌被发现具有参与合成铁载体类化合物的基因(1000-1400bp)(MZ222387 和 MZ222388),在 BLAST 搜索中具有 99%的相似性,并显示出铁载体的产生。与临床重要病原菌的显著抗菌活性以及编码抗菌代谢物的基因的存在表明,海洋异养细菌萎缩芽孢杆菌 SHB2097 可用于开发针对新兴抗生素耐药性的抗菌药物。